Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for determining smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Metrics to compare | NYMXF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYMXFPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.6x | −0.4x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | −1.0x | 0.7x | 2.6x | |
Price / LTM Sales | - | 9.5x | 3.3x | |
Upside (Analyst Target) | - | 329.2% | 43.3% | |
Fair Value Upside | Unlock | 23.7% | 6.9% | Unlock |